Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 3/20 | 0.46 |
| ▸ | GHSR | Q92847 | 6/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CCKBR | P32239 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2118652 | 0.87 | TRIM24 (0.48) | TRIM24GHSRMAPTPOLBCYP3A4 | |
| SCHEMBL2118328 | 0.86 | TRIM24 (0.45) | TRIM24GHSRBRD4MAPTALPL | |
| SCHEMBL2119299 | 0.85 | P2RX7 (0.43) | GHSRBRD4MAPTPTGES2MEN1 | |
| SCHEMBL2119284 | 0.84 | TRIM24 (0.45) | TRIM24GHSRBRD4MAPTALPL | |
| SCHEMBL2120142 | 0.81 | TRIM24 (0.46) | TRIM24GHSRMAPTALPLMEN1 | |
| SCHEMBL2119290 | 0.81 | TRIM24 (0.55) | TRIM24GHSRMAPTPOLBCYP3A4 | |
| SCHEMBL2118125 | 0.80 | TRIM24 (0.48) | TRIM24MAPTPOLBCYP3A4MEN1 | |
| SCHEMBL2116901 | 0.80 | TRIM24 (0.49) | TRIM24GHSRMAPTPOLBCYP3A4 | |
| SCHEMBL2118182 | 0.80 | TRIM24 (0.54) | TRIM24GHSRMAPTPTGES2POLB | |
| SCHEMBL2118706 | 0.80 | TRIM24 (0.45) | TRIM24GHSRMAPTALPLPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | ELARA PHARMACEUTICALS GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
| EP-2382190-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS | European Molecular Biology Laboratory (EMBL) (DE) | 2011-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | HIF1A, HIF1AN, EGLN3 | TRIM24 2142/4885GHSR 1390/4885BRD4 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.